Talk:Streptococcus mutans

From Wikipedia, the free encyclopedia

	This article is supported by WikiProject Dentistry. If you would like to participate, please visit the project page where you can join the project or you can direct questions about the rating system here.
Start	rated as start-Class on the assessment scale
???	This article has not yet received an importance rating on the assessment scale.

Should a discussion of this company's work be included?

http://www.oragenics.com/product_replacement.php

Quadm 02:36, 18 January 2007 (UTC)

At this point, probably not. If the product is shown to be effective and has more recent (and accessible) scientific data to demonstrate the company's claims, then I'd personally say yes. -- MarcoTolo 03:29, 27 January 2007 (UTC)

Based on the company's recent finances, Oragenics may not be around for very long. Interestingly, they have been developing a second front to preventing tooth decay along with gum disease. As for the 'Replacement Therapy' Quadm referred to above, the rights of the technology are held by the University of Florida, which can then license them to someone else. Something else to watch for is Planet Biotechnology, which is developing a drug called CaroRx that will help prevent tooth decay by preventing S. mutans from attaching to the tooth. It is currently in Phase II clinical testing. I don't know what their financial status is and if they will be able to bring it to the market. -- LtGen 01:00, 6 June 2007 (UTC)